Increased IL-1β levels are associated with an imbalance of “oxidant/antioxidant” status during Behçet’s disease
- 3 Downloads
Behçet’s disease is a multisystem disease. It stands at the crossroad between the autoimmunity and auto-inflammatory disorders. In this study, we sought to address a relationship that might exist between interleukin-1β (IL-1β) and the oxidants/antioxidants markers in Behçet’s patients.
Behçet’s disease patients (n = 78: active stage, n = 28; inactive stage, n = 50) and 41 healthy controls have been included in our study. In this context, we investigated the plasma levels of IL-1β and the nitrosative/oxidative markers: nitric oxide (NO), advanced oxidative protein products (AOPP) and fatty acids peroxidation-malondialdehyde (MDA). The antioxidant system was assessed by measuring the plasma level of superoxide dismutase (SOD) activity. The Mann-Whitney’s U and Pearson’s correlation tests were used for statistical analyses.
Our case-control study showed that patients in active stage displayed higher plasma levels of IL-1β, NO, AOPP and MDA versus healthy controls and patients in inactive stage. Patients in active stage showed significantly lower SOD levels related to patients in inactive stage and healthy controls respectively, whereas patients in inactive stage showed statistically insignificant SOD level versus healthy controls. Correlation studies showed a significant positive correlation between IL-1β and AOPP, IL-1β and NO, and negative correlation between IL-1β and SOD among Behçet’s disease patients. In addition, we showed positive correlation between AOPP and NO, AOPP and MDA and negative correlation between NO and SOD, AOPP and SOD in Behçet’s disease patients.
Interestingly, our study revealed that IL-1β levels increased and correlated with an imbalance of oxidants/antioxidants system, especially during active stage of Behçet disease. Collectively, our study indicates a possible link between IL-1β production and nitrosative/oxidative markers during Behçet’s disease. Exploiting this relationship might provide valuable outputs in the follow-up and prognosis of Behçet’s disease with a potential therapeutic value.
Key wordsBehçet’s disease IL-1β oxidative/nitrosative markers activation loop
Unable to display preview. Download preview PDF.
- 5.Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet’s disease: correlations with disease activity and severity. Isr J Med Sci 1995; 31(6): 345–8.Google Scholar
- 11.Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet’s disease. Clin Exp Rheumatol 2001; 19(24): 19–24.Google Scholar
- 19.Ben-Chetrit E, Cohen R, Chajek-Shaul T. Familial mediterranean fever and Behçet’s disease-are they associated? J Rheumatol 2002; 29: 530–4.Google Scholar
- 21.Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544–9.Google Scholar
- 22.Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behçet’s disease. J Rheumatol 1990; 17(10): 1428–9.Google Scholar
- 23.Katayama T, Tachinami K, Ishiguro M, Kubota Y. The relation between Behçet’s disease and interleukin-1 beta production. Nippon Ganka Gakkai Zasshi 1994; 98(2): 197–201.Google Scholar
- 27.Nur Rifaioglu E, Bülbülşen B, Ekiz Ö, Cigdem Dogramaci A. Neutrophil to lymphocyte ratio in Behçet’s disease as a marker of disease activity. Acta Dermatovenerol Alp Panonica Adriat 2014; 23: 65–67..Google Scholar
- 28.Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Autooxidative damage in Behçet’s disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49(1): 247–55.Google Scholar
- 32.Sandikci R, Türkmen S, Güvenen G, et al. Lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet’s disease. Acta Dermatovenerol 2003; 83(5): 342–6.Google Scholar
- 35.Belguendouz H, Messaoudene D, Lahmar K, et al. Interferon-γ and nitric oxide production during Behçet uveitis: immunomodulatory effect of interleukin-10. J Interferon Cytokine Res 2001; 31(6): 43–51.Google Scholar
- 37.Akdeniz N, Esrefoglu M, Keleş MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet’s disease. Ann Acad Med Singapore 2004; 33(5): 596–9.Google Scholar
- 38.Belguendouz H, Lahmar-Belguendouz K, Messaoudene D, et al. Cytokines modulate the “immune-metabolism” interactions during Behçet disease: effect on arginine metabolism. Int J Inflamm 2015; 9: 241738.Google Scholar
- 44.Kiraz S, Ertenli I, Calguneri M, et al. Interactions of nitric oxide and superoxide dismutase in Behçet’s disease. Clin Exp Rheumatol 2001; 19(24): S25–9.Google Scholar